Evidence map›Paper›PMID 41971792›Full record

ArticleFundamental research2026

Rational engineering of cholesterol-modified prodrug nanoassemblies for improving the tumor selectivity and safety of mitoxantrone.

Bowen Zhang, Wenyuan Liu, Jinrui Liu, Minglong Huang, Yaqiao Li, Erwei Zhao, Lurong Zhang, Xianbao Shi, Jin Sun, Zhonggui He and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Fundamental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bowen ZhangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Wenyuan LiuGeneral Hospital of Northern Theater Command, Shenyang 110016, China.
Jinrui LiuWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Minglong HuangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Yaqiao LiWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Erwei ZhaoWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Lurong ZhangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Xianbao ShiDepartment of Pharmacy, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.
Jin SunWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Zhonggui HeWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Lingxiao LiWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Bingjun SunWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitoxantrone (MTO) is an anthraquinone antitumor drug with potent therapeutic benefits. However, its clinical application is restricted by the severe side effects stemming from poor tumor selectivity. In this study, MTO and cholesterol (CLS) were conjugated via a tumor-selective disulfide bond to obtain the MTO-SS-CLS prodrug. Interestingly, the MTO-SS-CLS could self-assemble into uniform nanoassemblies, and the addition of DSPE-PEG

Indexed as

CholesterolDisulfide bondsMitoxantroneProdrug nanoassembliesTumor selectivity

Identifiers

PMID41971792
PMCPMC13069603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.